Crossmark

Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)—ViLen-01 protocol

Crossref DOI link: https://doi.org/10.1007/s00277-016-2776-x

Published Online: 2016-08-22

Published Print: 2016-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

Mittelman, Moshe https://orcid.org/0000-0001-7677-9119
Filanovsky, Kalman

Ofran, Yishai

Rosenbaum, Hanna

Raanani, Pia

Braester, Andrei

Goldschmidt, Neta

Kirgner, Ilya

Herishanu, Yair

Perri, Chava

Ellis, Martin

Oster, Howard S.
Funding

Funding for this research was provided by:

Celgene (US)
License Information

License valid from 2016-08-22